Virax Managing Director Dr Robert Crombie said
“TCN-P is a highly promising asset presenting
an outstanding clinical and commercial opportunity
with robust IP, GMP manufacturing complete with ample drug supply
and prestigious US cancer centres already dosing patient
s
.
Virax Managing Director Dr Robert Crombie said “TCN-P is a...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
